Shutai Shen: Subsidiary's product, POMITASE α for injection, included in the 2026 National Medical Insurance Catalog
2026-11-16 18:34:34
According to CoinMeta, ShuTaishen announced that in accordance with the "2026 National Medical Insurance Catalog" issued by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security, the product Pomitase α for injection (Bojiaying) produced by its subsidiary, Jiangsu Beijietai Biotechnology Co., Ltd., has been included in the "2026 National Medical Insurance Catalog." The medical insurance classification is Category B, with the code number 59. The indications are for the treatment of bleeding in adult patients with congenital hemophilia A or B who are deficient in coagulation factors VIII or IX and require gt; it is used at a dose of 5 Bethesda units (BU).
Bullish 0
Bearish 0
Source:Jin10 Data
This content is for market information only and does not constitute investment advice.